mild transthyretin familial amyloid polyneuropathy (TTR-FAP)

Pfizer’s Vyndaqel a success for rare disease

8 August 2016 | By Pfizer

Treatement over varying periods of up to 5.5 years, showed that early stage treatment with Vyndaqel resulted in minimal neurological disease progression, and in preservation of body weight, which often declines as the disease progresses...